Results 161 to 170 of about 85,257 (242)

Durable complete remission of pulmonary metastases with bevacizumab plus olaparib maintenance therapy in homologous recombination-deficient gynecologic large-cell neuroendocrine carcinoma: A case report. [PDF]

Gynecol Oncol Rep
Iida Y, Saito Y, Shimazaki M, Ichikawa T, Irie T, Matsushima J, Iizuka M, Takakura S.   +7 more
europepmc   +1 more source

Master Regulator SMC1A, Stabilized by N6‐Methyladenosine Reader IGF2BP1, Promotes HCC Progression Through Facilitating Enhancer–Promoter Interaction of Nestin

Advanced Science, Volume 13, Issue 43, 3 August 2026.
IGF2BP1‐mediated m6A stabilization sustains SMC1A expression, enabling cohesin‐associated chromatin regulation of Nestin in hepatocellular carcinoma. This work reveals an epitranscriptomic‐chromatin‐cytoskeletal regulatory axis linked to malignant phenotypes and identifies SMC1A as a biologically relevant vulnerability in HCC.
Zhenxiang Peng, Diguang Wen, Lu Zeng, Lin Lv, Shengtao Liao, Wenguang Zhang, Zhechuan Mei, Chuanfei Li   +7 more
wiley   +1 more source

Biomarker-guided immuno-angiogenic therapy in biliary tract cancer: insights from IMbrave151. [PDF]

J Gastrointest Oncol
Cisarovsky C, Chau I.
europepmc   +1 more source

Low‐Dose Antiangiogenic Therapy With Different Chemotherapy Backbones Among Patients With Heavily Pretreated Metastatic Breast Cancer

Cancer Innovation, Volume 5, Issue 4, August 2026.
Antiangiogenic‐based regimens demonstrated superior efficacy compared to chemotherapy alone in heavily pretreated MBC patients, with manageable AEs. ABSTRACT Background The prognosis for metastatic breast cancer (MBC) remains poor, and treatment options are limited for patients with heavily pretreated disease. Although antiangiogenic agents may provide
Yuanyi Wang, Yalong Qi, Cheng Zeng, Ruixia Song, Yuhan Wei, Haili Qian, Fei Ma   +6 more
wiley   +1 more source

Paradoxical Pyogenic Granuloma Associated With Ramucirumab but Not Bevacizumab: A Case Suggesting Differential Effects of VEGF Receptor and Ligand Inhibition. [PDF]

Respirol Case Rep
Nigi A, Iwamoto K, Itani H, Kondou S.
europepmc   +1 more source

Up to Four‐Year Outcomes of Single‐Fraction Stereotactic Radiosurgery for Small Brain Metastases: A Competing‐Risk Analysis

Cancer Medicine, Volume 15, Issue 8, August 2026.
ABSTRACT Introduction Single‐fraction stereotactic radiosurgery (SRS) is recommended for small brain metastases (< 2 cm). However, long‐term outcomes accounting for competing risks—particularly death, which precludes observation of local treatment failure (LTF)—remain limited. Methods We retrospectively analyzed cumulative incidences of LTF, defined as
Isabella Gruber, Oliver Koelbl
wiley   +1 more source

Systemic Bevacizumab Therapy in Recurrent Respiratory Papillomatosis: First Preliminary Study From Azerbaijan. [PDF]

Laryngoscope Investig Otolaryngol
Hashimli R, Aliyeva A.
europepmc   +1 more source

Tumor‐infiltrating lymphocyte (TIL) therapy: Historical context, clinical applications, and future directions

Cancer, Volume 132, Issue 15, 1 August 2026.
Abstract In the past 15 years, immunotherapy has become a major strategy for cancer therapy. Tumor‐infiltrating lymphocyte (TIL) therapy has been under investigation for nearly four decades and received its first Food and Drug Administration approval in 2024, when lifileucel was approved for patients with previously treated metastatic melanoma.
Shen Li, Alexandra E. Rojek, Reid Shaw, Cristina O’Donoghue, J. Michael Millis, Daniel J. Olson   +5 more
wiley   +1 more source

Efficacy of immunotherapy and targeted therapy for unresectable hepatocellular carcinoma: analysis of survival curves. [PDF]

Front Med (Lausanne)
Zhou W, Xu P.
europepmc   +1 more source

Survival Impact of Programmed Cell Death Ligand‐1 Expression in Patients With Epithelial Ovarian Carcinoma

Cancer Reports, Volume 9, Issue 8, August 2026.
ABSTRACT Aims To evaluate the proportion of expressed programmed cell death ligands‐1 (PD‐L1) in epithelial ovarian carcinoma patients, and the association with the clinicopathological, surgical outcomes, and oncologic outcomes. To compare PD‐L1 protein expression with messenger ribonucleic acid (mRNA) expression. Methods The patients who had pathology
Achjima Tankul, Suchanan Hanamornroongruang, Naravat Poungvarin, Rachawalan Suriyasaengsri, Sompop Kuljarusnont, Pornprom Ittiamornlert, Wathirada Karnchanabanyong, Irene Ruengkhachorn, Saowalak Hunnangkul   +8 more
wiley   +1 more source